Big Phama: No Vaccine til Safety and Efficacy Proven
Sept 9, 2020 3:51:24 GMT
sgard434 and tomsylver like this
Post by miamianne67 on Sept 9, 2020 3:51:24 GMT
Poster's note: As you may know Oxford/Moderna halted study to review severe reaction of one study member
Drug company chiefs sign pledge backing COVID-19 vaccine safety and efficacy
Sep. 8, 2020 10:55 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor
Nine drug company CEOs representing Pfizer (PFE -1.6%), BioNTech SE (BNTX +0.9%), AstraZeneca (AZN +1.1%), GlaxoSmithKline (GSK +1.1%), Johnson & Johnson (JNJ -0.8%), Merck (MRK -2.1%), Moderna (MRNA -8.0%), Sanofi (SNY +2.2%) and Novavax (NVAX -4.1%), have signed a pledge committing not to file for U.S. approval of their respective COVID-19 vaccines until safety and efficacy have been demonstrated through late-stage studies.
They emphasize that the "safety and well-being of vaccinated individuals" will always be their top priority, committing to maintain scientific and ethical standards in both development and manufacturing. They also pledge to ensure global supply.
The statement adds to growing list of public assurances by industry executives that they are not cutting corners in the sprint to the finish line, a perception held by many Americans.
Preliminary data from large-scale studies run by Pfizer/BioNTech, AstraZeneca and the University of Oxford and Moderna should be available this year. Pfizer has publicly stated that results from its trial may be available as soon as next month.
Last week, the CDC notified public health officials to prepare for the distribution of a vaccine as soon as late October/early November, a timeline that, critics say, appears politically motivated considering the November 3 election.
Drug company chiefs sign pledge backing COVID-19 vaccine safety and efficacy
Sep. 8, 2020 10:55 AM ET|About: Pfizer Inc. (PFE)|By: Douglas W. House, SA News Editor
Nine drug company CEOs representing Pfizer (PFE -1.6%), BioNTech SE (BNTX +0.9%), AstraZeneca (AZN +1.1%), GlaxoSmithKline (GSK +1.1%), Johnson & Johnson (JNJ -0.8%), Merck (MRK -2.1%), Moderna (MRNA -8.0%), Sanofi (SNY +2.2%) and Novavax (NVAX -4.1%), have signed a pledge committing not to file for U.S. approval of their respective COVID-19 vaccines until safety and efficacy have been demonstrated through late-stage studies.
They emphasize that the "safety and well-being of vaccinated individuals" will always be their top priority, committing to maintain scientific and ethical standards in both development and manufacturing. They also pledge to ensure global supply.
The statement adds to growing list of public assurances by industry executives that they are not cutting corners in the sprint to the finish line, a perception held by many Americans.
Preliminary data from large-scale studies run by Pfizer/BioNTech, AstraZeneca and the University of Oxford and Moderna should be available this year. Pfizer has publicly stated that results from its trial may be available as soon as next month.
Last week, the CDC notified public health officials to prepare for the distribution of a vaccine as soon as late October/early November, a timeline that, critics say, appears politically motivated considering the November 3 election.
Good catch, Miami